IP Library Granted Patent US 9,877,926
Granted Patent B2
US 9,877,926 · App. 14/379,303 · Granted Jan 30, 2018

Formulations and kits for forming bioadhesive matrices

Inventors: Meital Zilberman (Tel-Aviv, IL); Adaya Shefy-Peleg (Givataim, IL); Binyamin Cohen (Tiberias, IL); Maytal Foox (Nes Ziona, IL)
Assignee: Technology Innovation Momentum Fund (Israel) Limited Partnership
A61K9/70A61K31/192A61K31/44A61K47/12A61K47/36A61K47/42A61L24/043A61L24/08A61L24/104
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,877,926
App. No.
14/379,303
Granted
Jan 30, 2018
Kind
B2
Abstract

A bioadhesive formulation, comprising gelatin, alginate and a coupling agent, capable of forming a bioadhesive matrix, which is characterized by rapid curing, optimal viscosity, high bonding strength, flexibility, biocompatibility and biodegradability, is disclosed. Further disclosed is such a bioadhesive formulation which further comprises a bioactive agent, and a drug-eluting bioadhesive matrix formed therefrom, the bioadhesive matrix being capable of delivering the bioactive agent to a bodily site. Methods utilizing the bioadhesive formulations and matrices in various biological and medical procedures are also disclosed.

Claims (36)

1. A bioadhesive matrix formed by preparing a bioadhesive formulation and allowing a curing time to lapse, wherein said bioadhesive formulation comprises:

a) gelatin;

b) alginate;

c) a coupling agent; and

d) water,

wherein:

the concentration of said gelatin in the formulation ranges from 50 mg/ml to 400 mg/ml,

the concentration of said alginate in the formulation ranges from 10 mg/ml to 60 mg/ml, and

the concentration of said coupling agent ranges from 10 mg/ml to 30 mg/ml,

and wherein the concentrations of the components are selected such that, prior to curing, the formulation is characterized by a room temperature viscosity that ranges from 1 Pa-sec to 50 Pa-sec, and such that the curing time for forming said matrix ranges from 5 seconds to 30 minutes.

2. The matrix of claim 1 , wherein the concentrations of the components of said bioadhesive formulation are selected such that said matrix is characterized by at least one of:

a bonding strength of viable biological objects that ranges from 2,000 pascal to 60,000 pascal;

a flexural strength at physiological conditions that ranges from 0.5 MPa to 200 MPa; and

a biodegradability rate that ranges from 7 days to 6 months.

3. The matrix of claim 1 , wherein the concentration of said gelatin in the formulation ranges from 100 mg/ml to 300 mg/ml.

4. The matrix of claim 1 , wherein, in said formulation, the concentration of said gelatin ranges from 200 mg/ml to 300 mg/ml and the concentration of said alginate ranges from 20 mg/ml to 40 mg/ml.

5. The matrix of claim 1 , wherein said formulation further comprises a crosslinking promoting agent.

6. The matrix of claim 5 , wherein said crosslinking promoting agent is N-hydroxysuccinimide.

7. The matrix of claim 5 , wherein, in said formulation, the concentration of said gelatin ranges from 200 mg/ml to 300 mg/ml, the concentration of said alginate ranges from 20 mg/ml to 40 mg/ml, the concentration of said coupling agent ranges from 10 mg/ml to 20 mg/ml, and the concentration of said crosslinking promoting agent ranges from 5% to 20% relative to the amount of said coupling agent in the formulation.

8. The matrix of claim 1 , further comprising a bioactive agent.

9. The bioadhesive matrix of claim 1 , further comprising a bioactive agent sequestered therein, the bioadhesive matrix being a drug-eluting bioadhesive matrix.

10. A method of forming a bioadhesive matrix, the method comprising preparing a bioadhesive formulation and allowing a curing time to elapse, wherein said bioadhesive formulation comprises:

a) gelatin;

b) alginate;

c) a coupling agent; and

d) water,

wherein:

the concentration of said gelatin in the formulation ranges from 50 mg/ml to 400 mg/ml,

the concentration of said alginate in the formulation ranges from 10 mg/ml to 60 mg/ml, and

the concentration of said coupling agent ranges from 10 mg/ml to 30 mg/ml,

and wherein the concentrations of the components are selected such that, prior to curing, the formulation is characterized by a room temperature viscosity that ranges from 1 Pa-sec to 50 Pa-sec, and such that the curing time for forming said matrix ranges from 5 seconds to 30 minutes.

11. The bioadhesive matrix of claim 1 , comprising gelatin and alginate covalently coupled to one another and at least one bioactive agent sequestered therein, being characterized by at least one of:

a bonding strength of viable biological objects that ranges from 2,000 pascal to 60,000 pascal;

a flexural strength at physiological conditions that ranges from 0.5 MPa to 200 MPa; and

a biodegradability rate that ranges from 7 days to 6 months.

12. The matrix of claim 11 , being positioned between at least two objects, at least one of said objects being a biological object.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2019
From: TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP
To: ACTIVE HEALING BIOMEDICAL LTD.
Reel/Frame 048331/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2014
From: ZILBERMAN, MEITAL; SHEFY-PELEG, ADAYA; COHEN, BINYAMIN; FOOX, MAYTAL
To: TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP
Reel/Frame 033859/0360 →
Continuity (2)
Provisional Application 61599486 · Feb 16, 2012
Related Publication 20150038424A1 · Feb 5, 2015